canada clinical guidance

Motor neurone disease

A Canadian clinical summary of motor neurone disease, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CMAJ ALS

Source-attributed clinical priorities

  • Refer progressive mixed upper- and lower-motor-neuron features urgently to a multidisciplinary ALS clinic.
  • Monitor respiratory, bulbar, nutritional, communication, mobility and cognitive or behavioural needs proactively.
  • Discuss disease-modifying treatment, symptom care and advance planning early while preserving patient choice.
  • Do not delay referral while completing every mimic investigation when progressive motor-neuron signs are present.
sources for this section:CMAJ ALS

Practical assessment and management workflow

1
Document progression by region, upper and lower motor signs, bulbar symptoms, weight and respiratory complaints.
2
Assess spirometry or other respiratory measures, swallowing, nutrition, communication and mobility early.
3
Coordinate disease-modifying therapy eligibility and symptom treatment through a multidisciplinary ALS clinic.
4
Revisit equipment, caregiver support, ventilation, feeding and advance-care preferences before crises develop.
sources for this section:CMAJ ALS

Safety, red flags and urgent escalation

  • Orthopnea, weak cough, aspiration, rapid weight loss or declining respiratory measures needs urgent ALS-team review.
  • Avoid supplemental oxygen alone for neuromuscular hypoventilation without ventilation assessment.
  • Do not assume cognition is preserved; screen for behavioural and frontotemporal change when decisions are affected.
sources for this section:CMAJ ALS

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CMAJ ALS

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CMAJ ALS

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Medical Association JournalCanadian best practice recommendations for the management of amyotrophic lateral sclerosisaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.